ISTANBUL, June 10, 2026 /PRNewswire/ -- Zoomlion Heavy Industry Science & Technology Co., Ltd. ("Zoomlion") attracted widespread attention at KOMATEK 2026 in Istanbul with the appearance of its humanoid robot Z01. Alongside more than 40 high-end construction machinery exhibits that secured orders exceeding RMB 1 billion, Z01 emerged as one of the event's most talked-about attractions.

Designed for industrial collaboration, intelligent guidance, and educational applications, the bipedal humanoid robot demonstrated coordinated movement and precise operational capabilities throughout the exhibition. During a live demonstration, Z01 performed a Tai Chi routine, showcasing advanced motion control, dynamic balance, and human-robot interaction capabilities, drawing large crowds of visitors.

The debut of Z01 highlights Zoomlion's growing commitment to embodied AI, with embodied AI robots and related emerging industries forming the company's third growth curve.

Zoomlion possesses significant advantages in embodied intelligence development. As one of the earliest companies in China's construction machinery industry to invest in industrial IoT technologies, the company has built a strong digital foundation through Zvalley, its AI-powered industrial internet subsidiary, which is supported by nearly 1,300 technical and R&D professionals.

Since 2024, Zoomlion has accelerated the development of embodied AI technologies through its integrated hardware-software innovation capabilities. The company has established a comprehensive technology framework covering robot hardware, core components, decision-making and motion-control systems, and software ecosystems. At the same time, the integration of AI and robotics technologies is helping drive the intelligent transformation of Zoomlion's construction machinery, agricultural machinery, and mining equipment businesses.

By the end of 2025, Zoomlion had developed eight embodied AI robot prototypes across four major categories, creating a diversified product portfolio that includes humanoid and wheeled robots. Leveraging the company's extensive industrial environments, these robots have been validated in real-world applications at Zoomlion Smart City, including logistics handling, factory inspection, loading and unloading, pre-assembly, and quality inspection. These deployments have provided valuable operational data and experience for future large-scale commercialization.

Earlier this year at Hannover Messe 2026, Zoomlion showcased Robot Ops, its embodied AI development platform, and demonstrated collaborative operations involving humanoid and logistics robots. The event highlighted the company's progress in moving embodied AI from laboratory research to practical, industrial-grade applications, emphasizing real-world adaptability, autonomous decision-making, and multi-robot collaboration.

Today, embodied AI robots are already being utilized across multiple manufacturing processes within Zoomlion Smart City. Zoomlion is committed to developing embodied intelligence with an industrial mindset, focusing on real-world scenarios and building capabilities from the ground up. By establishing a robust industrial data system for embodied AI and advancing engineering-oriented robot design and manufacturing, the company is steadily laying the foundation for the large-scale deployment of embodied intelligence technologies across industries.

Mainland Chinese authorities are poised to invest approximately RMB2 trillion over the next five years to build nationwide data centers to support the domestic AI industry, Citi said in a report that, citing foreign media. Chinese telecom operators will be responsible for operating these data centers and will use at least 80% domestically produced AI accelerators.

In the broker's view, this new initiative will benefit foundries SMIC (00981.HK) and HUA HONG GRACE (01347.HK); OSAT players CHANG ELEC TECH (600584.SH) and TONGFU MICROELECTRONICS (002156.SZ); equipment suppliers ASMPT (00522.HK) and VITAL DEEPTECH (600641.SH); as well as AI accelerator vendors, as it provides a clearer roadmap for China’s AI localization.

The broker expected the target of more than 80% localization of AI chips to be achievable, as domestic AI chipmakers have already effectively captured the vast majority of China’s AI accelerator market share this year, while imports of NVIDIA Corporation (NVDA.US) H200 have largely stalled.

The broker opined this will also be more favorable for small- and mid-sized AI chipmakers, as state-backed data centers are more willing to procure from a broader range of suppliers.
~

AASTOCKS Financial News
Website: www.aastocks.com

BOSTON and SHENZHEN, China, June 10, 2026 /PRNewswire/ -- XtalPi (2228.HK), a leading platform in artificial intelligence (AI) and robotics-driven drug discovery, today announced a strategic partnership with a prominent international biopharmaceutical company. The collaboration focuses on developing a best-in-class small molecule against a G protein-coupled receptor (GPCR). This agreement builds upon a rigorous and successful pilot phase, where XtalPi's integrated quantum physics and AI algorithms delivered breakthrough hit rates, confirming the platform's capacity to tackle this complex metabolic target.

Under the agreement, the partner will provide an upfront payment and fully fund XtalPi's early R&D efforts. In addition, XtalPi is also eligible to receive preclinical, clinical, and commercial milestones, along with future royalties, bringing the total potential deal value to over $400 million. This partnership underscores the industry's strong confidence in XtalPi's scientific infrastructure and reinforces XtalPi's competitive edge and sustainable growth in conquering high-value targets.

Navigating Structural Blind Spots
The specific GPCR target receptor central to this collaboration exhibits extreme conformational plasticity, making its active pockets notoriously difficult for small molecules to selectively engage. Compounding this challenge is the absence of publicly available co-crystal structures of this receptor bound to small-molecule ligands. Operating within this structural blind spot, traditional high-throughput screening (HTS) methods frequently fall short in delivering molecules that satisfy the stringent, multidimensional requirements for potency, subtype selectivity, and oral bioavailability.

To bypass the structural data void with this highly dynamic GPCR, XtalPi's R&D team deployed multiscale enhanced sampling simulations to rigorously map the receptor's functional conformational landscape and implemented a dynamic, multi-conformational screening strategy.

Leveraging advanced quantum physics models and AI algorithms, XtalPi executed highly efficient virtual screening across hundreds of millions of commercial compounds. The company then applied its proprietary XFEP (Free Energy Perturbation) platform for precise binding affinity prediction.

Scaling R&D with a Closed-Loop AI and Robotics Engine
Entering the comprehensive collaboration phase, XtalPi will fully deploy its structure-based rational drug design platform. By seamlessly integrating quantum physics, generative AI, and large-scale automated chemical synthesis orchestrated by a Multi-Agent system, XtalPi will drive rapid Design-Make-Test-Analyze (DMTA) cycles.

This automated laboratory infrastructure bridges the historical gap between computational design and wet-lab synthesis and validation, continuously generating novel drug candidates optimized for high potency and ideal ADMET (absorption, distribution, metabolism, excretion, and toxicity) profiles. Ultimately, this approach aims to significantly expand the druggable chemical space and shorten discovery timelines, accelerating the translation of cutting-edge computational breakthroughs into substantial clinical assets for patients worldwide.

"This collaboration underscores our deep commitment to supporting top-tier biopharmaceutical companies with robust, scalable AI and robotics capabilities," said Dr. Shuhao Wen, Chairman at XtalPi. "At XtalPi, we design our platform to act as the essential infrastructure for innovation—helping our partners reliably translate complex biological challenges into strong pipeline assets. We are excited to combine our technological strengths with our partner's clinical vision to advance accessible, highly effective oral therapies in the metabolic space."

About XtalPi

XtalPi Holdings Limited (XtalPi, 2228.HK) was founded in 2015 by three physicists from the Massachusetts Institute of Technology (MIT). It is an innovative R&D platform powered by quantum physics, artificial intelligence, and robotics. By integrating first-principles calculations, AI algorithms, high-performance cloud computing, and standardized automation systems, XtalPi provides digital and intelligent R&D solutions for companies in the pharmaceutical, materials science, agricultural technology, energy, new chemicals, and cosmetics industries.

中國深圳和波士頓2026年6月10日 /美通社/ -- 全球領先的AI+機器人新藥與新材料研發平台晶泰科技（2228.HK）今日宣布，已與一家管線豐富且擁有多款商業化產品的國際知名生物制藥公司達成總額超4億美元的AI藥物發現戰略合作。雙方將針對一個GPCR（G蛋白偶聯受體）靶點，共同開發具備「同類最佳（Best-in-Class）」潛力的創新口服小分子藥物。

根據協議，合作方將向晶泰科技支付首付款並承擔所有的早期研發費用，晶泰科技還將獲得臨床前、臨床及商業化里程碑付款，以及未來的銷售分成，項目潛在總金額超4億美元。這種將近期研發收入與長期管線資產價值深度綁定的合作模式，既有效降低了晶泰科技參與高壁壘靶點研發的成本與風險，又鎖定了重磅藥物的高彈性回報空間。此次合作不僅體現了前沿藥企對晶泰研發實力的深厚信賴，更再次印證了晶泰平台在攻克難成藥、高價值靶點上的競爭優勢與可持續增長能力。

破解復雜 GPCR 的小分子「難成藥」困局

本次合作所聚焦的GPCR靶點存在多亞型動態平衡，其天然結合口袋極難被小分子精準靶向，全球範圍內尚無小分子與其結合的共晶結構的公開報道。面對此類「結構盲區」，傳統的高通量篩選（HTS）難以同時優化活性、選擇性與藥代屬性等核心指標並產出具有競爭力的分子候選，現有在研小分子管線項目均處於早期臨床階段。

面對這一結構生物學難題，晶泰科技利用其先進的計算藥物研發平台，顯著提升了苗頭化合物發現的效率與精度，實現了從傳統「大海撈針」到「智能導航」的轉變，在客戶的先導項目中展現了卓越的創新突破與交付能力。

晶泰團隊以多尺度增強採樣模擬技術成功「解碼」了該靶點的關鍵構象，採用多構象協同篩選策略，顯著提升發現高潛力的活性分子的可能性。在先導項目中，依托先進的量子物理模型與AI算法，晶泰科技對億級規模的商業化化合物庫進行了高效虛擬篩選，並利用XFEP自由能微擾平台精準預測分子親和力，大幅提高篩選分子的命中率，獲得客戶的高度認可，直接促成並加速了本次戰略合作的簽署。

自動化與 AI 引擎：規模化重塑新藥研發範式

進入全面合作後，晶泰科技將啟用其融合量子物理與AI的結構理性藥物設計平台，結合大規模自動化化學合成，全面賦能快速的 DMTA（設計-合成-測試-分析）循環。其自動化實驗室在Multi-Agent的統籌下，源源不斷地產出兼具良好活性，新穎結構及理想藥代動力學（ADMET）屬性的候選分子，大幅擴展可成藥化學空間，並縮短研發周期。雙方的強強聯手，有望加速把尖端計算生物學突破轉化為惠及全球的實質性管線資產。

晶泰科技董事局主席溫書豪博士表示：「此次戰略合作的達成，是晶泰『AI+機器人』底層研發系統在全球頂級生物制藥舞台上的又一次實戰驗證。我們將繼續發揮晶泰的平台優勢，為賦能全球創新藥研發打造『新基建』，將兼具挑戰性與巨大市場價值的生物學難題轉化為具有高潛力的管線資產。期待我們的合作能成功攻堅代謝領域的重磅口服療法，為全球患者帶來更便捷、高效的治療方案。」

關於晶泰科技

晶泰科技（「XtalPi Holdings Limited」，股份簡稱：晶泰控股，XTALPI，股票代碼：2228.HK）由三位麻省理工學院的物理學家於 2015 年創立，是一個基於量子物理、以人工智能賦能和機器人驅動的創新型研發平台。公司採用基於量子物理的第一性原理計算、人工智能、高性能雲計算以及可擴展及標準化的機器人自動化相結合的方式，為制藥及材料科學（包括農業技術、能源及新型化學品以及化妝品）等產業的全球和國內公司提供藥物及材料科學研發解決方案及服務。

• COPD study initiation expands SKB378/WIN378 development into a second major respiratory disease
• SKB378/WIN378 is currently being evaluated in the Phase 2/3 POLARIS asthma study, with initial Phase 2 data expected in the second half of 2026
• SKB378/WIN378 has the potential to be the first-to-market, ultra long-acting anti-TSLP antibody for asthma and COPD, with Phase 3 initiation in asthma planned for Q4 2026

CHENGDU, China, June 9, 2026 /PRNewswire/ -- Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. ("Kelun-Biotech" or the "Company") today announced that its partner Windward Bio has dosed the first patients in the Phase 2 SIRIUS study of SKB378/WIN378 (also known as HBM9378) in patients with chronic obstructive pulmonary disease (COPD).

COPD is a progressive, irreversible lung disease and the third leading cause of death worldwide. Driven by immune-mediated airway inflammation and persistent airflow obstruction, the disease makes even routine daily activities a struggle. Its defining feature is exacerbations — sudden, severe flare-ups that lead to emergency room visits, hospitalizations, and lasting declines in lung function. Despite currently available inhaled background therapies, more than 3 million patients with moderate-to-severe COPD remain at high risk of recurrent exacerbations, underscoring an urgent need for better treatment options.

SIRIUS is a global, Phase 2 randomized, double-blind, placebo-controlled, dose-finding study. It is designed to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of SKB378/WIN378 in patients with moderate-to-severe COPD.

SKB378/WIN378 started as a co-development project jointly conducted by the Company and Harbour BioMed, with both parties equally sharing global rights.

About SKB378/WIN378 (also known as HBM9378)

SKB378/WIN378 is a next-generation, fully human monoclonal antibody that potently inhibits the TSLP ligand. This clinically validated target plays a key role in the development and progression of a wide array of immunological diseases, including asthma and COPD. SKB378/WIN378 has been engineered to achieve half-life extension (HLE) and silenced effector function. It has been studied in a Phase 1 trial, which confirmed an extended half-life suitable for twice-yearly dosing, demonstrated a low rate of antidrug antibodies, and was safe and well tolerated up to the highest dose tested. SKB378/WIN378 is administered subcutaneously. Windward Bio licensed the global rights (excluding Greater China and several Southeast and West Asian countries) for SKB378/WIN378 from Kelun-Biotech and Harbour BioMed (also known as HBM9378). WIN378 is currently being evaluated in the POLARIS Phase 2/3 asthma study with initial readouts expected in the second half of 2026. WIN378 is also being evaluated in the SIRIUS Phase 2 COPD study. The first Phase 3 study of WIN378 in asthma is expected to begin in the fourth quarter of 2026.

About Kelun-Biotech 

Kelun-Biotech (6990.HK) is a holding subsidiary of Kelun Pharmaceutical, which focuses on the R&D, manufacturing, commercialization and global collaboration of innovative biological drugs and small molecule drugs. Kelun-Biotech focuses on major disease areas such as solid tumors, autoimmune, and metabolic diseases, and in establishing a globalized drug development and industrialization platform to address the unmet medical needs in China and the rest of world. Kelun-Biotech is committed to becoming a leading global enterprise in the field of innovative drugs. At present, Kelun-Biotech has more than 30 ongoing key innovative drug projects, of which 4 projects with 8 indications have been approved for marketing, 1 project is in the NDA stage and more than 10 projects are in the clinical stage. Kelun-Biotech has established one of the world's leading proprietary ADC and novel DC platforms, OptiDC™, and has 2 ADC projects with 5 indications approved for marketing, and multiple ADC and novel DC assets in clinical or preclinical research stage. For more information, please visit https://en.kelun-biotech.com/. 

About Windward Bio

Windward Bio is a clinical-stage biotechnology company with deep discovery, development, and commercialization expertise committed to transforming the treatment of people living with serious immunological conditions. Its lead program is WIN378, a potential best-in-disease, ultra long-acting anti-TSLP monoclonal antibody currently in a Phase 2/3 trial for asthma and in a Phase 2 study for COPD. The pipeline also includes WIN027, a clinical-stage, long-acting anti-TSLPxIL-13 bispecific with broad therapeutic potential across immunological diseases, which is currently in Phase 1. The company is building a discovery pipeline of long-acting bispecific antibodies, targeting validated biology in respiratory and dermatological conditions.

• 該項治療COPD研究的啟動，將SKB378/WIN378的研發拓展至第二個重大呼吸系統疾病
• 目前，SKB378/WIN378正在進行治療哮喘的II/III期POLARIS研究，II期初步資料預計於2026年下半年讀出
• SKB378/WIN378有潛力成為首款獲批上市的超長效抗TSLP抗體，用於治療哮喘和COPD；其治療哮喘的III期研究計畫於2026年第四季度啟動

成都2026年6月9日 /美通社/ -- 四川科倫博泰生物醫藥股份有限公司（簡稱「科倫博泰」或「公司」）今日宣佈，其合作夥伴Windward Bio主導的一項用於評估SKB378/WIN378（亦稱HBM9378）治療慢性阻塞性肺疾病（COPD）的II期SIRIUS研究，已完成首批患者給藥。

COPD是一種進展性、不可逆的肺部疾病，是全球第三大致死原因。該疾病由免疫介導的氣道炎症和持續氣流受限驅動，使患者的日常活動困難重重。其顯著特徵是病情急性加重——突發的嚴重惡化會導致急診就診、住院以及肺功能的持續下降。儘管目前已有吸入性基礎療法，但仍有超過300萬中重度COPD患者面臨反復急性發作加重的風險，因此對更優治療方案有迫切需求。

SIRIUS是一項全球性、隨機、雙盲、安慰劑對照、劑量探索的II期研究，旨在評估SKB378/WIN378在中重度COPD患者中的安全性、耐受性、藥代動力學和藥效學。

SKB378/WIN378最初由科倫博泰與和鉑醫藥共同開發，雙方平分其全球權益。

關於SKB378/WIN378（亦稱HBM9378）

SKB378/WIN378是一種新一代全人源單克隆抗體，能強效抑制胸腺基質淋巴細胞生成素（TSLP）配體。這一經過臨床驗證的靶點在多種免疫性疾病的發生與進展中起關鍵作用，包括哮喘和COPD。SKB378/WIN378已經過工程化設計，以實現延長的半衰期及效應功能沉默。一項SKB378/WIN378的Ⅰ期臨床試驗證實了其支持延長給藥間隔的半衰期，抗藥抗體發生率較低，且在最高測試劑量下仍具有良好的安全性和耐受性。SKB378/WIN378可通過皮下給藥。

Windward Bio自科倫博泰（亦稱 SKB378）與和鉑醫藥（亦稱 HBM9378）獲得了SKB378/WIN378 的全球權利（不包括大中華區及數個東南亞和西亞國家）。目前，WIN378正在進行一項治療哮喘的II/III期POLARIS研究，初步資料預計於2026年下半年讀出；同時也在開展一項治療COPD的II期SIRIUS研究。WIN378治療哮喘的首個III期研究預計於2026 年第四季度啟動。

關於科倫博泰

四川科倫博泰生物醫藥股份有限公司(簡稱「科倫博泰」，股票代碼：6990.HK)是科倫藥業控股子公司，專注于創新生物技術藥物及小分子藥物的研發、生產、商業化及國際合作。公司圍繞全球和中國未滿足的臨床需求，重點佈局腫瘤、自身免疫和代謝等重大疾病領域，建設國際化藥物研發與產業化平臺，致力於成為在創新藥物領域國際領先的企業。公司目前擁有30余個重點創新藥項目，其中4個項目8個適應症已獲批上市，1個專案處於NDA階段，10餘個專案正處於臨床階段。公司成功構建了享譽國際的專有ADC及新型偶聯藥物平臺OptiDC^TM，已有2個ADC項目5個適應症獲批上市，多個ADC或新型偶聯藥物產品處於臨床或臨床前研究階段。更多資訊請訪問官網https://kelun-biotech.com/。

關於Windward Bio

Windward Bio是一家處於臨床階段的生物技術公司，在創新療法發現、開發及商業化領域具備深厚專長，致力於改變嚴重免疫性疾病患者的治療方式。其核心項目WIN378是一款潛在同類最佳、超長效抗TSLP單克隆抗體，目前正在開展針對哮喘的II/III期研究，以及針對COPD的II期研究。Windward Bio的管線還包括一款處於臨床階段的長效抗TSLP×IL-13雙特異性抗體WIN027，在多種免疫性疾病中具有廣泛治療潛力，目前處於I期臨床階段。Windward Bio正在構建針對呼吸系統疾病與皮膚疾病已驗證靶點的長效雙特異性抗體管線。

Google under Alphabet Inc. (GOOGL.US) has placed an order with Intel Corporation (INTC.US) to produce more than 3 million tensor processing units (TPUs) in 2028, according to online media outlet The Information, citing people with direct knowledge of the matter.

Intel Corporation surged 11.2% overnight (8th), closing at USD110.27.

NVIDIA Corporation (NVDA.US) is reportedly evaluating whether Intel’s technology can be used to manufacture a processor that integrates four graphics chips into a single unit, but it has not yet placed an order.

Spiking demand for chips amid the AI boom has made it difficult for Taiwan Semiconductor Manufacturing Company Ltd. (TSM.US) to provide sufficient supply, report noted. This capacity crunch has prompted several major AI chip design companies to turn to Intel.
~

AASTOCKS Financial News
Website: www.aastocks.com

SHANGHAI, June 9, 2026 /PRNewswire/ -- Everest Medicines (HKEX 1952.HK, "Everest", or the "Company"), a biopharmaceutical company focused on the discovery, clinical development, manufacturing, and commercialization of innovative therapeutics, today announced that it has entered into an exclusive licensing agreement with Jiangsu Vcare PharmaTech Co., Ltd. ("Vcare PharmaTech"), for the development, registration and commercialization of Sumecigrel (formerly known as Vicagrel) across the Asia-Pacific region, including Southeast Asia, South Korea, Australia, Hong Kong SAR, Macao SAR, and Taiwan region, China. Pursuant to the agreement, Everest Medicines will pay Vcare PharmaTech an upfront payment of RMB 20 million, along with subsequent milestone payments and commercial supply procurement.

This collaboration strengthens the Company's cardiovascular portfolio and highlights Everest's continued focus on the Asia-Pacific market, supporting the advancement of its regional strategy and the development of innovative therapies.

Sumecigrel is an antiplatelet agent and a new-generation oral P2Y12 receptor antagonist. It is being clinically developed for the treatment and prevention of atherothrombotic events such as acute coronary syndrome (ACS), ischemic stroke (IS) and peripheral arterial disease (PAD). As a novel antithrombotic drug self-developed by Vcare PharmaTech, the product is currently advancing preparations for NDA in China, the United States, Europe.

The molecular design of Sumecigrel targets the black box warning associated with clopidogrel resistance. It innovatively optimizes the metabolic pathway of clopidogrel while retaining its active metabolite, striking a better balance between therapeutic benefits and bleeding risks inherent to antiplatelet medications. Featuring faster onset of action, lower dosage, more stable efficacy, better controllable bleeding risks, reduced metabolic burden and broader clinical applicability, Sumecigrel is a novel antiplatelet candidate with prominent Best-in-Class potential. It is expected to address the increasingly personalized demands for antithrombotic therapy and become a blockbuster product in the antithrombotic market.

"This collaboration with Vcare PharmaTech marks another step in strengthening our presence in the Asia-Pacific region," said Mr. Yifang Wu, Chairman of the Board of Everest Medicines. "Sumecigrel is a next-generation oral P2Y12 receptor antagonist with Best-in-Class potential, offering differentiated clinical benefits and complementing Everest's cardiovascular pipeline. Leveraging our clinical, regulatory, and commercial capabilities across the Asia-Pacific as a global platform for innovative therapies, Everest will drive Sumecigrel's development and commercialization to realize its full clinical and commercial value and bring new treatment options to more patients."

"As our self-developed novel antithrombotic drug, Sumecigrel represents our first innovative pharmaceutical product, "said Dr. Gong Yanchun, Co-founder, Chairman and CEO of Vcare PharmaTech. "This strategic partnership with Everest Medicines serves as the first step of Sumecigrel's global commercialization strategy, creating a win-win situation for an original innovation enterprise and an international commercial platform. Powered by AI-driven differentiated original design, Vcare PharmaTech consistently focuses on the development of innovative drugs and leading therapies, standing as a pioneer of the next-generation original innovation in the global antiplatelet field. We will accelerate the global R&D and registration progress of Sumecigrel, consolidate its global competitive edges, and contribute Chinese innovation to the diagnosis and treatment of cardiovascular diseases across the Asia-Pacific and the world at large."

Cardio-cerebrovascular diseases rank among the leading causes of death worldwide. Related fatalities rose sharply to 17.9 million in 2019, accounting for approximately 32% of all global deaths. Around 85% of these deaths were attributed to myocardial infarction (a major type of ACS) and stroke. The death toll from cardio-cerebrovascular diseases further climbed to 19.2 million in 2023.

Antiplatelet drugs inhibit platelet activation, adhesion and aggregation to reduce thrombotic risks, and are widely used for the prevention and treatment of atherothrombotic diseases. P2Y12 receptor antagonists are a major category of mainstream antiplatelet medications. Currently marketed products in this class continue to face challenges in balancing variability in efficacy and bleeding risk across patients, and optimizing the overall clinical benefit–risk profile remains an important unmet medical need in this therapeutic area.

As a next-generation P2Y12 receptor antagonist, Sumecigrel has completed Phase I, Phase II, China-US PK/PD bridging study and Phase III clinical trials. It has demonstrated favorable efficacy and safety with solid clinical value, and is poised to become an improved treatment option for patients with ACS, IS and PAD.

About Sumecigrel

Sumecigrel is the world's first new-generation P2Y12 receptor antagonist designed to resolve clopidogrel's heavy reliance on CYP2C19 genetic polymorphism by optimizing its metabolic pathway while retaining clopidogrel's active metabolite. It is indicated for atherothrombotic events including acute coronary syndrome, ischemic stroke and peripheral arterial disease. It stands as one of Vcare PharmaTech's flagship achievements underpinned by the philosophy of differentiated original design to tackle unmet clinical needs.

Its molecular design findings were published in Journal of Medicinal Chemistry (JMC), a top journal of the American Chemical Society, and highlighted by SciBX under Nature Portfolio, which recognized it as one of the most commercially promising projects in the field of novel drugs. Currently in preparation for NDA submissions in multiple countries, Sumecigrel possesses strong Best-in-Class potential and broad commercial prospects, and is expected to reshape the antithrombotic market where no new innovative drugs targeting the same mechanism have been launched for over a decade.

About Everest Medicines

Everest Medicines is a biopharmaceutical company focused on discovering, developing, manufacturing and commercializing innovative pharmaceutical products that address critical unmet medical needs for patients in global markets. The management team of Everest Medicines has deep expertise and an extensive track record both in China and with leading global pharmaceutical companies.

The Company's therapeutic areas of focus include CKM (cardiovascular, kidney, and metabolic), autoimmune, ophthalmology and critical care. Everest Medicines has developed a fully integrated commercialization platform that combines omnichannel commercial capabilities with end-to-end product lifecycle management. Leveraging its proprietary mRNA platform, the Company is advancing its existing pipeline, including mRNA in vivo CAR-T and mRNA cancer vaccines, while selectively expanding into additional high-value therapeutic areas with blockbuster potential, and accelerating its global expansion. For more information, please visit the Company's website: www.everestmedicines.com.

About Vcare PharmaTech

Founded in 2010 by professors from China Pharmaceutical University and overseas returnee talents, Vcare PharmaTech is a commercial-stage innovative biopharmaceutical enterprise adopting AI-enabled differentiated original drug design and dedicated to developing innovative drugs and leading therapies. The Company has built a full-spectrum innovation system covering the entire R&D and industrialization lifecycle of new drugs, from AI-powered differentiated project initiation and preclinical candidate discovery to integrated pharmaceutical development and green manufacturing.

It houses the Nanjing Key Laboratory for AI-Driven Drug Design and Nanjing Engineering Research Center for Synthetic Biology and Flow Chemistry.

Focused on addressing unmet clinical demands via differentiated approaches, Vcare PharmaTech develops a tiered, high-quality and diversified pipeline of innovative drugs targeting treatment resistance, drug resistance and targeted selectivity optimization. Its product portfolio covers major chronic disease areas including inflammation and autoimmunity, cardio-cerebrovascular diseases and oncology, striving to deliver superior treatment solutions for patients worldwide. For more information, please visit www.vcarepharmatech.com.

Forward-Looking Statements

This news release may make statements that constitute forward-looking statements, including descriptions regarding the intent, belief or current expectations of the Company or its officers with respect to the business operations and financial condition of the Company, which can be identified by terminology such as "will," "expects," "anticipates," "future," "intends," "plans," "believes," "estimates," "confident" and similar statements. Such forward-looking statements are not guarantees of future performance and involve risks and uncertainties, or other factors, some of which are beyond the control of the Company and are unforeseeable. Therefore, the actual results may differ from those in the forward-looking statements as a result of various factors and assumptions, such as future changes and developments in our business, competitive environment, political, economic, legal and social conditions. The Company or any of its affiliates, directors, officers, advisors or representatives has no obligation and does not undertake to revise forward-looking statements to reflect new information, future events or circumstances after the date of this news release, except as required by law.

Chip technology company Marvell Technology, Inc. (MRVL.US) last leaped 7% in pre-market trading on Monday (8th), last reported at USD281.88.

Index operator S&P Dow Jones Indices announced that Marvell Technology, Inc. and electronics manufacturer Flex Ltd. (FLEX.US) will be added to the S&P 500 Index, with the changes taking effect at the open of US trading on Monday, June 22.

Flex Ltd. gained 3.3% in pre-market trading, last at USD156.98. The Campbell's Company (CPB.US) and Pool Corporation (POOL.US) will be removed from the index at the same time.
~

AASTOCKS Financial News
Website: www.aastocks.com

SAN FRANCISCO and SUZHOU, China, June 8, 2026 /PRNewswire/ -- Innovent Biologics, Inc. ("Innovent") (HKEX: 01801), a world-class biopharmaceutical company that develops, manufactures and commercializes high quality medicines for the treatment of oncology, cardiovascular and metabolic, autoimmune, ophthalmology and other major diseases, presented multiple clinical and preclinical results of its innovative metabolic and obesity pipeline at the 2026 American Diabetes Association's^® (ADA) Scientific Sessions. This includes three clinical oral presentations of mazdutide (GCG/GLP-1 dual agonist) across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, as well as preclinical data from its IBI3032 and IBI3042, as next‑generation oral daily and weekly GLP‑1 receptor agonists, along with IBI3040 (a novel amylin analog) and IBI3046 (an INHBE-targeting siRNA). Innovent Biologics' differentiated pipeline aims to provide scientific and comprehensive treatment options for weight management and metabolic comorbidities through offering superior tolerability, reduced muscle loss, convenient dosing, durable efficacy, and integrated comorbidity management.

Below is a summary of its early-stage pipeline results:

IBI3032 (daily oral small-molecule GLP-1) Preclinical and Phase 1 Clinical Study Results

Preclinical results:

ADA Reference: IBI3032: An Orally Bioavailable Nonpeptidic GLP-1 Receptor Agonist Advancing Through Phase 1 Clinical Trials (Abstract No.: 1678-P)

IBI3032 is a novel, orally bioavailable non-peptidic GLP-1R agonist discovered via structure-based design, and has now advanced into Phase 1 clinical trials in both China and the United States.

IBI3032 exhibited potent activation of the human GLP-1R (EC₅₀ = 0.53 nM) with high selectivity and minimal β-arrestin recruitment. IBI3032 demonstrated favorable cross‑species pharmacokinetics and a robust preclinical efficacy profile. Pharmacokinetic studies revealed high oral exposure in cynomolgus monkeys, with a bioavailability of 24.5% and a half-life of 6.3 hours.

Importantly, compared to the marketed small‑molecule GLP‑1R agonist Orforglipron, IBI3032 demonstrates significantly superior weight‑loss efficiency—achieving markedly greater body weight loss at half of the dose in preclinical models. In a 28-day study in hGLP-1R knock-in DIO mice, oral IBI3032 produced dose-dependent body weight loss relative to vehicle (1 mg/kg: -1.8%; 6 mg/kg: -8.0%; 12 mg/kg: -10.8%). In a 28-day cynomolgus monkey study, once-daily oral administration of IBI3032 (1 mg/kg) produced 11.2% body weight loss versus vehicle.

This differentiated profile supports its potential as a best‑in‑class oral therapy. Collectively, these findings underscore IBI3032 as a next‑generation oral GLP‑1R agonist that combines true oral convenience, low‑dose efficacy, and accelerated global clinical development.

Phase 1 clinical results:

ADA Reference: Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics of IBI3032, a Novel Oral Nonpeptide GLP-1 Receptor Agonist: Single- and Multiple-Ascending Dose Studies in Chinese Adults (Abstract No.: 1690-P)

Preclinical studies indicate IBI3032 has a higher oral exposure than other marketed oral small‑molecule GLP‑1 in cynomolgus monkeys and shows encouraging efficacy signals for weight loss in obese cynomolgus monkeys. Based on these preclinical findings, two Phase 1 studies were designed to preliminarily assess the human dose range, weight-loss efficacy signals, and safety and tolerability of IBI3032, further validate the hypothesis of potent weight loss at low doses, and provide key data to inform the subsequent clinical trial design.

Study Design: The single-ascending dose (SAD) study recruited 40 eligible participants with/without overweight or obesity (BMI 20–40 kg/m²) to receive once-daily single doses of IBI3032 at 0.3 mg, 1.0 mg, 3.0 mg and 6.0 mg. The multiple-ascending dose (MAD) study recruited a total of 79 overweight/obese participants (BMI 24–40 kg/m²) to receive once-daily oral IBI3032 for 4 weeks per protocol-specified dose titration ranging from 0.6 mg to 10 mg, aiming to evaluate multiple dose-escalation titration regimens.

Clinical Study Findings:

• Linear pharmacokinetics properties support once-daily oral administration: After a single oral dose, IBI3032's systemic exposure (AUC_inf and C_max) increased in an approximately dose-proportional manner across 0.3–6 mg dose range; peak plasma concentration (T_max) occurred 5–12 hours post-dose. Its terminal elimination half-life is (T_1/2) approximately 2 days, which supports a once-daily dosing regimen. Pharmacokinetics (PK) parameters after 4 weeks of sequential titration in MAD were consistent with SAD and exhibited linear PK characteristics.
• Overall manageable safety profile: IBI3032 showed a manageable safety profile in both SAD and MAD studies; nearly all treatment-emergent adverse events were mild to moderate, with no treatment-related serious adverse events reported. No cases of acute pancreatitis, acute kidney injury, acute gallbladder disease, major adverse cardiovascular events, thyroid C-cell hyperplasia or thyroid carcinoma were reported in either study.
• Gradual dose titration balances weight-loss efficacy and treatment tolerability: Four-week cohort comparisons within MAD study demonstrated that low starting dose with stepwise dose escalation enables substantial weight reduction alongside meaningful improvement in gastrointestinal tolerability. In the cohort starting at 0.6 mg with seven-step escalation to 9 mg (n=12), 4-week treatment led to an average 10.11% body weight reduction after 4 weeks, while vomiting incidence remained at 8.3%. Compared with other cohorts utilizing the aggressive escalation approach with high starting doses and large dose increments, this slow titration regimen with lower initial dose, smaller incremental jumps and prolonged escalation cycle lowers gastrointestinal adverse event risk while retaining weight-lowering efficacy, providing evidence for future clinical dosing regimen development.

Ongoing Development in Phase 1: Additional Phase 1 clinical study of IBI3032 is ongoing to further explore and refine optimal dose titration schemes. Leveraging its differentiated attributes of superior oral exposure and low effective therapeutic dose, the program aims to validate the molecule's potential of potent weight loss under acceptable safety and tolerability.

IBI3040 (novel Amylin) Preclinical Results

ADA Reference: IBI3040, a Novel Amylin Analog, Induces Superior Weight Loss in Preclinical Models (Abstract No.: 3077-LB)

IBI3040 is a highly potent agonist of the amylin and calcitonin (CTR) receptors. In a 2-week study in DIO rats, IBI3040 at 2 and 10 nmol/kg Q3D resulted in dose-dependent reductions in body weight of 8.82% and 11.11%, respectively, compared to vehicle-treated rats. In another study, the combination of IBI3040 and semaglutide resulted in a greater weight reduction of −14.7%, whereas monotherapy with IBI3040 or semaglutide produced weight losses of −10.12% and −3.01% in DIO rats, respectively, indicating an additive effect of the combined treatment. Compared to cagrilintide, IBI3040 displays a favorable PK profile, high solubility, and stability without fibril formation at physiological pH (7-8).

IBI3040 demonstrates superior receptor activation, robust weight loss effects compared to cargrilintide and eloralintide, and synergistic potential with semaglutide, supporting its development as a next-generation amylin analog for obesity treatment.

IBI3042 (weekly oral small-molecule GLP-1) Preclinical Results

ADA Reference: IBI3042: A Novel Oral Once-Weekly Small-Molecule GLP-1 Receptor Agonist for Type 2 Diabetes and Obesity (Abstract No.: 2543-P)

IBI3042 is potentially the world's first once-weekly oral small-molecule GLP-1 receptor agonist candidate entering clinical studies by the end of 2026. The weekly dosing potential is offering a compelling new option for patients seeking a more convenient and manageable long-term treatment for type 2 diabetes and obesity.

IBI3042 exhibited GLP-1R activation in cAMP assays, but showed no β-arrestin recruitment in NanoBiT assays. In human GLP-1 receptor knock-in (GLP-1R KI) mice, IBI3042 (0.4 mg/kg P.O.) maintained significant glucose-lowering effects for at least 7 days, outperforming Orforglipron at the same dose.

In diet-induced obese (DIO) humanized GLP-1 receptor knock-in mice, IBI3042 at 1 mg/kg twice weekly showed comparable efficacy to Orforglipron 1.5 mg/kg once daily, while the 3 mg/kg twice-weekly dose demonstrated superior efficacy. In contrast, Orforglipron at 3 mg/kg twice weekly showed no notable efficacy.

In obese cynomolgus monkeys, IBI3042 produced robust, dose-dependent body weight reduction with twice-weekly oral dosing (1.5–4.5 mg/kg). The 1.5 mg/kg twice-weekly regimen achieved efficacy comparable to Orforglipron 1 mg/kg once daily, while the 4.5 mg/kg twice-weekly regimen demonstrated superior body weight reduction. Furthermore, the 7 mg/kg once-weekly regimen also matched the efficacy of Orforglipron 1 mg/kg once daily.

These compelling results position IBI3042 as a promising once-weekly oral treatment for obesity and type 2 diabetes, delivering a significantly more convenient and effective dosing option for patients.

IBI3046 (novel INHBE siRNA) Preclinical Results

ADA Reference: IBI3046, an INHBE siRNA, Enables High Quality and Long-Lasting Weight Control in Preclinical Study (Abstract No.: 2662-P)

IBI3046 is an INHBE-silencing RNAi therapeutic designed to enhance adipose lipolysis with sustained effects.

IBI3046 demonstrated potent and durable mRNA knockdown in hINHBE KI mouse model. In the efficacy study, IBI3046 resulted in a 13% reduction in body weight and a 50% decrease in fat mass relative to control. In combination therapy, IBI3046 administered with a low dose of GLP-1RA achieved 20% body weight loss and a 80% reduction in fat mass. Combining IBI3046 with GLP-1RAs may synergistically enhance fat loss while mitigating key limitations of current anti-obesity regimens. In addition, IBI3046 extended the duration of suppressed weight regain following drug withdraw.

IBI3046 enables Q3M-6M dosing, offering diabetes and obesity patients improved adherence and quality of life for glucose and weight control, thereby can potentially redefine the standard of metabolic disease management.

Dr. Lei Qian, Chief R&D Officer (General Biomedicine) of Innovent, stated, "At this year's ADA Scientific Sessions, we are pleased to present a series of new data in obesity and metabolic diseases, which is an important step in establishing Innovent as an emerging leader and innovator in this field. The multiple oral presentations of mazdutide, across adults with type 2 diabetes and obesity, adults with obesity and adolescents with obesity, further highlight its differentiated profile as a GCG/GLP‑1 dual receptor agonist in terms of weight loss, glycemic control and metabolic benefits. In addition, the data on IBI3032 (oral daily GLP-1 small molecule), IBI3042 (oral weekly GLP-1 small molecule), IBI3040 (amylin) and IBI3046 (INHBE siRNA) represent key progresses of our next‑generation obesity pipeline with global potential, which are designed to address unmet needs around tolerability, muscle preservation, dosing convenience, durability of weight loss and management of obesity‑related comorbidities."

About Innovent

Innovent is a leading biopharmaceutical company founded in 2011 with the mission to empower patients worldwide with affordable, high-quality biopharmaceuticals. The company discovers, develops, manufactures and commercializes innovative medicines that target some of the most intractable diseases. Its pioneering therapies treat cancer, cardiovascular and metabolic, autoimmune and eye diseases. Innovent has launched 18 products in the market. It has 1 asset under NMPA review, 4 assets in Phase 3 or pivotal clinical trials and 14 more molecules in early clinical stage. Innovent partners with over 30 global healthcare companies, including Eli Lilly, Roche, Takeda, Sanofi, Incyte, LG Chem and MD Anderson Cancer Center.

Guided by the motto, "Start with Integrity, Succeed through Action," Innovent maintains the highest standard of industry practices and works collaboratively to advance the biopharmaceutical industry so that first-rate pharmaceutical drugs can become widely accessible. For more information, visit www.innoventbio.com, or follow Innovent on Facebook and LinkedIn.

Forward-looking statement

This news release may contain certain forward-looking statements that are, by their nature, subject to significant risks and uncertainties. The words "anticipate", "believe", "estimate", "expect", "intend" and similar expressions, as they relate to Innovent Biologics ("Innovent"), are intended to identify certain of such forward-looking statements. The Company does not intend to update these forward-looking statements regularly.

These forward-looking statements are based on the existing beliefs, assumptions, expectations, estimates, projections and understandings of the management of the Company with respect to future events at the time these statements are made. These statements are not a guarantee of future developments and are subject to risks, uncertainties and other factors, some of which are beyond the Company's control and are difficult to predict. Consequently, actual results may differ materially from information contained in the forward-looking statements as a result of future changes or developments in our business, the Company's competitive environment and political, economic, legal and social conditions.

The Company, the Directors and the employees of the Company assume (a) no obligation to correct or update the forward-looking statements contained in this site; and (b) no liability in the event that any of the forward-looking statements does not materialise or turn out to be incorrect.